Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DPC expands offerings with Thermo Electron products:

This article was originally published in Clinica

Executive Summary

DPC has formed a pact with US scientific instrumentation company Thermo Electron, in which the Welsh diagnostics developer will distribute Thermo Electron's TCAutomation product line and clinical chemistry system in the UK. The TCAutomation product line, which Llanberis, Gwynedd-based DPC will market as the DPC LabStation, consists of several modules which can be bolted on in any combination to provide solutions tailored to each laboratory's needs - anything from a simple sample sorter to a complex total laboratory automation configuration. Waltham, Massachusetts-based Thermo Electron's clinical chemistry systems, which will be marketed by DPC as the DPC T Series analysers, are small- to mid-capacity chemistry systems for private, clinical or veterinary laboratories.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT051921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel